Eugia (UK) Limited
Registered name: EUGIA (UK) LIMITED
Part of Eugia Pharma B.V. groupEugia (UK) Limited made £143k revenue and £54.1k profit in the year to 31 Mar 2024.
Eugia (UK) Limited’s revenue grew 260% to £143k in the year to 31 Mar 2024, with £54.1k profit and 0 employees. The company is classified under “wholesale of pharmaceutical goods” and is based in Uxbridge; we hold 2 years of its filed accounts.
- Status
- Active
- Location
- Uxbridge, London
- Age
- 5 yrs · since 2021
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The directors consider the immediate and ultimate parent Company to be Eugia Pharma BV, a Company registered in the Netherlands and Aurobindo Pharma Limited a Company incorporated in India respectivel”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Mar 2023 | 31 Mar 2024 |
|---|---|---|
| Disclosure | Full P&L | Full P&L |
| Profit & loss | ||
| Revenue (turnover) | £39.5k | £143k |
| Gross profit | £39.5k | £143k |
| Operating profit | −£13k | £66.3k |
| Profit before tax | −£13k | £66.3k |
| Profit after tax | −£13k | £54.1k |
| Profit (best available) | −£13k | £54.1k |
| Employees (average) | 0 | 0 |
| Ratios | ||
| Profit margin | −33% | 37.9% |
| Gross margin | 100% | 100% |
| Growth (year on year) | ||
| Revenue growth | — | ▲260.4% |
| Balance sheet — indirect signals, not revenue | ||
| Cash at bank | £6.4k | £22.2k |
| Net assets | £407k | £461k |
| Fixed assets | £417k | £368k |
| Current assets | £26.2k | £122k |
| Debtors | £7.5k | £99.6k |
| Deferred income | £4.5k | £3.5k |
| Source | FullAccounts · bulk data Sep 2024 | FullAccounts · bulk data Sep 2024 |
How the business works
- Profit margin
- 37.9%
- Profit ÷ revenue.
- Gross margin
- 100%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- —
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 258.3%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 2.5%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 69.9%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▲13%
- Now £461k
- Cash at bank
- ▲246%
- Now £22.2k
- Headcount
- —
- Now 0
- Deferred income
- ▼22%
- Now £3.5k
- Fixed assets
- ▼12%
- Now £368k
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Ownership chain
- Eugia Pharma B.V. (registered outside the UK register)ultimate parent75–100%
- Eugia (UK) Limitedthis company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
Sources
Latest figures from FullAccounts for the year to 31 Mar 2024 (profit £54.1k), from the Companies House accounts bulk data published Sep 2024. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.